This article is more than 5 years old. Information may no longer be current.
Cardiology Today's Intervention top 5 articles posted in December
Cardiology Today’s Intervention compiled a list of the top 5 stories posted to Healio.com/Intervention in December.
This month, Cardiology Today’s Intervention readers were most interested in criteria for coronary revascularization in patients with ACS, the benefits of infrapopliteal DES, FDA approval for the use of heart pumps in high-risk PCI procedures, covered endovascular reconstruction of the aortic bifurcation as an alternative to surgery, the use of warfarin vs. apixaban as treatment for patients undergoing PCI and much more.
Societies release appropriate use criteria for coronary revascularization in patients with ACS
Seven professional societies released a report updating appropriate use criteria for determining whether and how to perform coronary revascularization in patients with ACS.
Infrapopliteal DES linked to lower rates of restenosis, TLR, amputation vs. other devices
Compared with plain balloon angioplasty or bare-metal stents, infrapopliteal drug-eluting stents appear to yield significantly lower rates of restenosis, target lesion revascularization and amputation, and promote wound healing, according to recent findings.
In the systematic review and Bayesian network meta-analysis, researchers identified randomized clinical trials comparing various endovascular devices for management of below-the-knee arteries.
Heart pump approved for use in high-risk PCI procedures
Abiomed announced that the FDA granted an expanded indication to one of its heart pumps for use in high-risk PCI procedures.
The pump (Impella CP) may now be used as temporary ventricular support for 6 hours or less to prevent hemodynamic instability and reduce risk for adverse events during high-risk PCI procedures, according to a press release issued by the company.
Novel endovascular approach viable option to surgery for significant aortoiliac disease
In patients with extensive aortoiliac occlusive disease, covered endovascular reconstruction of the aortic bifurcation may represent a viable alternative to surgery in complex lesions, according to findings presented at VEITHsymposium.
The researchers evaluated 95 elective patients (mean age, 60 years) who underwent a covered endovascular reconstruction of the aortic bifurcation (CERAB) procedure at a single center between October 2010 and July 2016. The median follow-up was 24 months.
Anticoagulants confer comparable risks for adverse events in patients undergoing PCI
NEW ORLEANS — The use of warfarin or apixaban produced similar bleeding and stroke rates in patients undergoing PCI, according to results presented at the American Heart Association Scientific Sessions.
Using data from the ARISTOTLE trial, David Kopin, MD, an internal medicine resident at Duke University Medical Center, and colleagues conducted a secondary analysis of the 18,201 patients to assess the frequency of PCI, rates of concomitant antiplatelet therapy use and post-PCI outcomes including stroke and bleeding.